Robert E. Dudley, Ph.D., has devoted his career to developing products that revolutionize healthcare for men. As the co-inventor of multiple formulations of testosterone replacement therapies, he is a leading voice in hypogonadism and men’s health. Driven by a mission to help men overcome the symptoms of hypogonadism, Dr. Dudley established Clarus Therapeutics, Inc. in 2004 and has served as Chief Executive Officer, President and Chairman of the Board of Directors since its founding. Dr. Dudley has more than 30 years of experience in the testosterone replacement therapy field. Most notably, he co-invented, led the discovery, development, regulatory approval and launch of the first testosterone gel product, AndroGel 1%. And while CEO of Clarus, he co-invented and led the development efforts to secure FDA approval of JATENZO, the first oral testosterone undecanoate product available in the U. S. Dr. Dudley received his Bachelor of Science in biology from Pepperdine University, Seaver College, his Master of Science in biology from the University of New Mexico, and his Ph.D., with honors, in Pharmacology and Toxicology from the University of Kansas School of Medicine.